These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 34106726)

  • 1. Characterization of a Nanovaccine Platform Based on an α1,2-Mannobiose Derivative Shows Species-non-specific Targeting to Human, Bovine, Mouse, and Teleost Fish Dendritic Cells.
    Pappalardo JS; Salmaso S; Levchenko TS; Mastrotto F; Bersani S; Langellotti CA; Vermeulen M; Ghersa F; Quattrocchi V; Zamorano PI; Hartner WC; Toniutti M; Musacchio T; Torchilin VP
    Mol Pharm; 2021 Jul; 18(7):2540-2555. PubMed ID: 34106726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo targeting of antigens to human dendritic cells through DC-SIGN elicits stimulatory immune responses and inhibits tumor growth in grafted mouse models.
    Kretz-Rommel A; Qin F; Dakappagari N; Torensma R; Faas S; Wu D; Bowdish KS
    J Immunother; 2007 Oct; 30(7):715-26. PubMed ID: 17893564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycan-based DC-SIGN targeting vaccines to enhance antigen cross-presentation.
    van Kooyk Y; Unger WW; Fehres CM; Kalay H; García-Vallejo JJ
    Mol Immunol; 2013 Sep; 55(2):143-5. PubMed ID: 23158834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-presentation through langerin and DC-SIGN targeting requires different formulations of glycan-modified antigens.
    Fehres CM; Kalay H; Bruijns SC; Musaafir SA; Ambrosini M; van Bloois L; van Vliet SJ; Storm G; Garcia-Vallejo JJ; van Kooyk Y
    J Control Release; 2015 Apr; 203():67-76. PubMed ID: 25656175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective targeting of dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN) with mannose-based glycomimetics: synthesis and interaction studies of bis(benzylamide) derivatives of a pseudomannobioside.
    Varga N; Sutkeviciute I; Guzzi C; McGeagh J; Petit-Haertlein I; Gugliotta S; Weiser J; Angulo J; Fieschi F; Bernardi A
    Chemistry; 2013 Apr; 19(15):4786-97. PubMed ID: 23417900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional interaction of common allergens and a C-type lectin receptor, dendritic cell-specific ICAM3-grabbing non-integrin (DC-SIGN), on human dendritic cells.
    Hsu SC; Chen CH; Tsai SH; Kawasaki H; Hung CH; Chu YT; Chang HW; Zhou Y; Fu J; Plunkett B; Su SN; Vieths S; Lee RT; Lee YC; Huang SK
    J Biol Chem; 2010 Mar; 285(11):7903-10. PubMed ID: 20080962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells.
    Unger WW; van Beelen AJ; Bruijns SC; Joshi M; Fehres CM; van Bloois L; Verstege MI; Ambrosini M; Kalay H; Nazmi K; Bolscher JG; Hooijberg E; de Gruijl TD; Storm G; van Kooyk Y
    J Control Release; 2012 May; 160(1):88-95. PubMed ID: 22366522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The physiological role of DC-SIGN: a tale of mice and men.
    Garcia-Vallejo JJ; van Kooyk Y
    Trends Immunol; 2013 Oct; 34(10):482-6. PubMed ID: 23608151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The dendritic cell-specific C-type lectin DC-SIGN is a receptor for Schistosoma mansoni egg antigens and recognizes the glycan antigen Lewis x.
    van Die I; van Vliet SJ; Nyame AK; Cummings RD; Bank CM; Appelmelk B; Geijtenbeek TB; van Kooyk Y
    Glycobiology; 2003 Jun; 13(6):471-8. PubMed ID: 12626400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody.
    Tacken PJ; de Vries IJ; Gijzen K; Joosten B; Wu D; Rother RP; Faas SJ; Punt CJ; Torensma R; Adema GJ; Figdor CG
    Blood; 2005 Aug; 106(4):1278-85. PubMed ID: 15878980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mouse DC-SIGN/CD209a as Target for Antigen Delivery and Adaptive Immunity.
    Schetters STT; Kruijssen LJW; Crommentuijn MHW; Kalay H; Ochando J; den Haan JMM; Garcia-Vallejo JJ; van Kooyk Y
    Front Immunol; 2018; 9():990. PubMed ID: 29867967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multimodal imaging of nanovaccine carriers targeted to human dendritic cells.
    Cruz LJ; Tacken PJ; Bonetto F; Buschow SI; Croes HJ; Wijers M; de Vries IJ; Figdor CG
    Mol Pharm; 2011 Apr; 8(2):520-31. PubMed ID: 21381651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation.
    Singh SK; Stephani J; Schaefer M; Kalay H; García-Vallejo JJ; den Haan J; Saeland E; Sparwasser T; van Kooyk Y
    Mol Immunol; 2009 Dec; 47(2-3):164-74. PubMed ID: 19818504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative binding and uptake of liposomes decorated with mannose oligosaccharides by cells expressing the mannose receptor or DC-SIGN.
    Gao H; Gonçalves C; Gallego T; François-Heude M; Malard V; Mateo V; Lemoine F; Cendret V; Djedaini-Pilard F; Moreau V; Pichon C; Midoux P
    Carbohydr Res; 2020 Jan; 487():107877. PubMed ID: 31766009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Internalizing antibodies to the C-type lectins, L-SIGN and DC-SIGN, inhibit viral glycoprotein binding and deliver antigen to human dendritic cells for the induction of T cell responses.
    Dakappagari N; Maruyama T; Renshaw M; Tacken P; Figdor C; Torensma R; Wild MA; Wu D; Bowdish K; Kretz-Rommel A
    J Immunol; 2006 Jan; 176(1):426-40. PubMed ID: 16365436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting
    Velasquez LN; Stüve P; Gentilini MV; Swallow M; Bartel J; Lycke NY; Barkan D; Martina M; Lujan HD; Kalay H; van Kooyk Y; Sparwasser TD; Berod L
    Front Immunol; 2018; 9():471. PubMed ID: 29662482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DC-SIGN mediated antigen-targeting using glycan-modified liposomes: formulation considerations.
    Joshi MD; Unger WW; van Beelen AJ; Bruijns SC; Litjens M; van Bloois L; Kalay H; van Kooyk Y; Storm G
    Int J Pharm; 2011 Sep; 416(2):426-32. PubMed ID: 21371544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo targeting of DC-SIGN-positive antigen-presenting cells in a nonhuman primate model.
    Pereira CF; Torensma R; Hebeda K; Kretz-Rommel A; Faas SJ; Figdor CG; Adema GJ
    J Immunother; 2007 Oct; 30(7):705-14. PubMed ID: 17893563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C-type lectin receptors MR and DC-SIGN are involved in recognition of hemocyanins, shaping their immunostimulatory effects on human dendritic cells.
    Villar J; Salazar ML; Jiménez JM; Campo MD; Manubens A; Gleisner MA; Ávalos I; Salazar-Onfray F; Salazar F; Mitchell DA; Alshahrani MY; Martínez-Pomares L; Becker MI
    Eur J Immunol; 2021 Jul; 51(7):1715-1731. PubMed ID: 33891704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogen recognition by DC-SIGN shapes adaptive immunity.
    Geijtenbeek TB; den Dunnen J; Gringhuis SI
    Future Microbiol; 2009 Sep; 4(7):879-90. PubMed ID: 19722841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.